Literature DB >> 9519711

The B-subunit of cholera toxin induces immunoregulatory cells and prevents diabetes in the NOD mouse.

D O Sobel1, B Yankelevich, D Goyal, D Nelson, A Mazumder.   

Abstract

The B-subunit of the cholera toxin molecule (CT-B) has T-cell immunomodulatory properties. Because the pathogenesis of diabetes in the nonobese diabetic (NOD) mouse model of IDDM is thought to be a T-cell-mediated process due to an imbalance of immunoregulatory and anti-islet effector cells, we examined the effect of CT-B administration on the development of diabetes in the NOD mouse and assessed whether this potential diabetes-sparing effect of CT-B is mediated by changes in immunoregulatory and/or anti-islet cytotoxic effector cell activity. The administration of either intravenous or intraperitoneal CT-B decreased the development of diabetes with no apparent drug toxicity. At 6 months of age, only 18% of CT-B vs. 75% of saline-treated animals had diabetes. Histopathological examination revealed less islet atrophy in CT-B-treated animals. The in vitro proliferative responses of mononuclear splenocytes and thymocytes to concanavalin A and lipolysaccharide and the proportion of B-cells and T-cell subsets were not altered by CT-B treatment. CT-B administration did not inhibit the primary immunization of mice to tetanus toxoid. The development of diabetes in irradiated NOD mice was slower in the animals injected with spleen cells (SC) from CT-B-treated than from saline-treated NOD mice, suggesting that CT-B decreases anti-islet effector cell activity. The injection of SC from CT-B-treated mice inhibited the adoptive transfer of diabetes by SC from diabetic mice into irradiated NOD mice, documenting that CT-B administration induces regulatory cell activity. In conclusion, CT-B administration prevents the development of diabetes in NOD mice by inhibiting the immune destruction of islets. This islet-sparing activity appears mediated, at least in part, by the induction of regulatory cells and, in turn, suppression of anti-islet effector cells, which is not associated with generalized immunosuppression or T- or B-cell depletion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9519711     DOI: 10.2337/diab.47.2.186

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  17 in total

Review 1.  Immunotherapy of immune-mediated diabetes. Present and future.

Authors:  N Maclaren
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

2.  Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells.

Authors:  A George-Chandy; K Eriksson; M Lebens; I Nordström; E Schön; J Holmgren
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

Review 3.  In search of a solution to the sphinx-like riddle of GM1.

Authors:  Robert W Ledeen; Gusheng Wu
Journal:  Neurochem Res       Date:  2010-11-13       Impact factor: 3.996

4.  Comparative proteomic analysis reveals activation of mucosal innate immune signaling pathways during cholera.

Authors:  Crystal N Ellis; Regina C LaRocque; Taher Uddin; Bryan Krastins; Leslie M Mayo-Smith; David Sarracino; Elinor K Karlsson; Atiqur Rahman; Tahmina Shirin; Taufiqur R Bhuiyan; Fahima Chowdhury; Ashraful Islam Khan; Edward T Ryan; Stephen B Calderwood; Firdausi Qadri; Jason B Harris
Journal:  Infect Immun       Date:  2015-01-05       Impact factor: 3.441

5.  Cholera toxin B subunit linked to glutamic acid decarboxylase suppresses dendritic cell maturation and function.

Authors:  Oludare Odumosu; Dequina Nicholas; Kimberly Payne; William Langridge
Journal:  Vaccine       Date:  2011-07-30       Impact factor: 3.641

6.  Suppression of dendritic cell activation by diabetes autoantigens linked to the cholera toxin B subunit.

Authors:  Oludare Odumosu; Kimberly Payne; Ineavely Baez; Jessica Jutzy; Nathan Wall; William Langridge
Journal:  Immunobiology       Date:  2010-09-24       Impact factor: 3.144

7.  Cholera toxin subunit B inhibits IL-12 and IFN-{gamma} production and signaling in experimental colitis and Crohn's disease.

Authors:  E M Coccia; M E Remoli; C Di Giacinto; B Del Zotto; E Giacomini; G Monteleone; M Boirivant
Journal:  Gut       Date:  2005-08-16       Impact factor: 23.059

8.  Escherichia coli enterotoxin B subunit triggers apoptosis of CD8(+) T cells by activating transcription factor c-myc.

Authors:  M Soriani; N A Williams; T R Hirst
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

9.  Protection of non-obese diabetic mice from autoimmune diabetes by Escherichia coli heat-labile enterotoxin B subunit.

Authors:  Thomas O Ola; Neil A Williams
Journal:  Immunology       Date:  2006-02       Impact factor: 7.397

10.  Modulation of human monocytes by Escherichia coli heat-labile enterotoxin B-subunit; altered cytokine production and its functional consequences.

Authors:  Victor Turcanu; Timothy R Hirst; Neil A Williams
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.